{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T09:39:19Z","timestamp":1779269959815,"version":"3.51.4"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.msard.2021.102875","type":"journal-article","created":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T12:47:19Z","timestamp":1614689239000},"page":"102875","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["No evidence of disease activity-3 (NEDA-3) status in patients with relapsing remitting multiple sclerosis: Evidence from Saudi cohort receiving mainly Interferon."],"prefix":"10.1016","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6027-7229","authenticated-orcid":false,"given":"Azra","family":"Zafar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2837-4891","authenticated-orcid":false,"given":"Foziah Jabbar Gossab","family":"AlShamrani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2021.102875_bib0001","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s00415-016-8049-8","article-title":"Prevalence of multiple sclerosis in the Lazio region, Italy: use of an algorithm based on health information systems","volume":"263","author":"Bargagli","year":"2016","journal-title":"J Neurol"},{"key":"10.1016\/j.msard.2021.102875_bib0002","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/S0140-6736(02)08220-X","article-title":"Multiple sclerosis","volume":"359","author":"Compston","year":"2002","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.msard.2021.102875_bib0003","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition","volume":"26","author":"Walton","year":"2020","journal-title":"Mult Scle"},{"key":"10.1016\/j.msard.2021.102875_bib0004","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3389\/fneur.2018.00201","article-title":"Commentary: global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the global burden of disease study 2015","volume":"9","author":"Karikari","year":"2018","journal-title":"Front Neurol"},{"key":"10.1016\/j.msard.2021.102875_bib0005","article-title":"Epidemiology and phenotypes of multiple sclerosis in the Middle East North Africa (MENA) region","volume":"6","author":"Yamout","year":"2020","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"10.1016\/j.msard.2021.102875_bib0006","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3988\/jcn.2018.14.3.359","article-title":"Clinical presentations and phenotypic spectrum of multiple sclerosis at a University Hospital in Saudi Arabia","volume":"14","author":"Nazish","year":"2018","journal-title":"J Clin Neurol"},{"issue":"15 Supplement","key":"10.1016\/j.msard.2021.102875_bib0007","article-title":"The nationwide National Multiple Sclerosis Registry (NMSR). Initial Results Saudi MS Registry study group*","volume":"90","author":"Al-Jumah","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.102875_bib0008","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12883-020-1629-3","article-title":"Rising prevalence of multiple sclerosis in Saudi Arabia, a descriptive study","volume":"20","author":"AlJumah","year":"2020","journal-title":"BMC Neurol"},{"key":"10.1016\/j.msard.2021.102875_bib0009","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1212\/WNL.0000000000000036","article-title":"Assessing treatment response to interferon-\u03b2: is there a role for MRI?","volume":"82","author":"Dobson","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.102875_bib0010","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.msard.2012.12.001","article-title":"Editors\u2019 welcome and a working definition for a multiple sclerosis cure","volume":"2","author":"Banwell","year":"2013","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2021.102875_bib0011","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1111\/ene.13669","article-title":"\u201cNo evidence of disease activity\u201d - is it an appropriate surrogate in multiple sclerosis?","volume":"25","author":"Hegen","year":"2018","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.msard.2021.102875_bib0012","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S1474-4422(11)70023-0","article-title":"Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis","volume":"10","author":"Giovannoni","year":"2011","journal-title":"Lancet Neurol"},{"issue":"Suppl 3","key":"10.1016\/j.msard.2021.102875_bib0013","first-page":"S3","article-title":"Freedom from disease activity in multiple sclerosis","volume":"74","author":"Havrdova","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.102875_bib0014","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1001\/jamaneurol.2014.3537","article-title":"Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort","volume":"72","author":"Rotstein","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.msard.2021.102875_bib0015","doi-asserted-by":"crossref","first-page":"788","DOI":"10.3389\/fneur.2019.00788","article-title":"Prospective assessment of no evidence of disease activity-4 status in early disease stages of multiple sclerosis in routine clinical practice","volume":"10","author":"Guevara","year":"2019","journal-title":"Front Neurol"},{"key":"10.1016\/j.msard.2021.102875_bib0016","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s40263-017-0482-4","volume":"32","author":"Guttman","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.msard.2021.102875_bib0017","unstructured":"17.Population Characteristics surveys. Saudi Arabia General Authority for Statistics. 2017. Available from: https:\/\/www.stats.gov.sa\/en\/565529."},{"key":"10.1016\/j.msard.2021.102875_bib0018","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.msard.2021.102875_bib0019","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.msard.2011.08.001","article-title":"Disease activity free status in MS","volume":"1","author":"Lublin","year":"2012","journal-title":"Mult Scler Relat Dis"},{"key":"10.1016\/j.msard.2021.102875_bib0020","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.msard.2018.10.020","article-title":"No evidence of disease activity status over 3 years in a real-world cohort of relapsing remitting MS patients in Germany","volume":"27","author":"Huhn","year":"2019","journal-title":"Mult Scler Relat Dis"},{"key":"10.1016\/j.msard.2021.102875_bib0021","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40893-017-0026-2","article-title":"Baseline characteristics associated with NEDA-3 status in fingolimod-treated patients with relapsing-remitting multiple sclerosis","volume":"2","author":"Giuliani","year":"2017","journal-title":"Mult Scler Demyelinating Dis"},{"key":"10.1016\/j.msard.2021.102875_bib0022","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1136\/jnnp-2015-310597","article-title":"Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study","volume":"87","author":"Cohen","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.msard.2021.102875_bib0023","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.15537\/smj.2019.11.24630","article-title":"Assessment of safety and effectiveness of oral multiple sclerosis medication","volume":"40","author":"Al Turaiki","year":"2019","journal-title":"Saudi Med J"},{"key":"10.1016\/j.msard.2021.102875_bib0024","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1177\/1352458513516531","article-title":"Multiple sclerosis in Isfahan, Iran: an update","volume":"20","author":"Etemadifar","year":"2014","journal-title":"Mult Scler"},{"key":"10.1016\/j.msard.2021.102875_bib0025","first-page":"767","article-title":"Door-to-door survey of major neurological disorders (project) in Al Quseir City, Red Sea Governorate, Egypt","volume":"9","author":"Tallawy","year":"2013","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.msard.2021.102875_bib0026","first-page":"221","article-title":"Clinical spectrum of multiple sclerosis at a tertiary care hospital in Pakistan","volume":"24","author":"Shahwar","year":"2008","journal-title":"Pak J Med Sci"},{"key":"10.1016\/j.msard.2021.102875_bib0027","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3109\/00207454.2011.565893","article-title":"Prevalence of multiple sclerosis in Dubai, United Arab Emirates","volume":"121","author":"Inshasi","year":"2011","journal-title":"Int J Neurosci"},{"key":"10.1016\/j.msard.2021.102875_bib0028","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/952321","article-title":"Future of management of multiple sclerosis in the Middle East: A consensus view from specialists in ten countries","author":"Aljumah","year":"2013","journal-title":"Mult Scler Int"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821001425?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821001425?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:51:21Z","timestamp":1761900681000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034821001425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":28,"alternative-id":["S2211034821001425"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.102875","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"No evidence of disease activity-3 (NEDA-3) status in patients with relapsing remitting multiple sclerosis: Evidence from Saudi cohort receiving mainly Interferon.","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.102875","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102875"}}